Astrazeneca Shares Climb 0.31% Amid Oncology Breakthroughs But Rank 316th in Trading Volume

Astrazeneca (AZN) rose 0.31% on 26 September, with a trading volume of $0.34 billion, ranking 316th in market activity. The pharmaceutical giant's shares gained traction amid renewed focus on its oncology pipeline and regulatory developments in key markets.

Recent updates highlighted a positive phase III trial outcome for its experimental lung cancer therapy, which demonstrated improved progression-free survival rates. Analysts noted this could position the treatment as a first-line option in specific patient cohorts, potentially expanding market access beyond initial projections. Regulatory filings also indicated expedited review timelines for a companion diagnostic test, which could streamline treatment eligibility assessments.

Investor sentiment was further supported by a strategic partnership announcement with a European biotech firm to co-develop novel immuno-oncology combinations. The collaboration grants Astrazeneca exclusive rights to advance two preclinical candidates into clinical trials, with data expected by mid-2026. Market participants interpreted the move as a strategic deepening of the company's oncology portfolio rather than a defensive acquisition.

To run this back-test accurately I need to pin down a few practical details that the system must know in order to generate the data set and execute the trade logic: 1. Universe: • Do you want all U.S. common stocks (NYSE + NASDAQ) or a different market? 2. Weighting & re-balancing: • Equal-weight each of the 500 names every day, with a full rebalance each trading day? (This is the common approach, but let me know if you prefer another weighting rule.) 3. Trade execution assumptions: • Enter at the next day’s open and exit at that day’s close (i.e., ~1-day holding period)? • Ignore transaction costs/slippage, or should we apply a specific cost per trade? 4. Benchmark (optional): • If you’d like the results compared against a benchmark (e.g., SPY), please specify. Once I have these items confirmed I can generate the data-retrieval plan and run the back-test.